Notice2024-04197
Meeting of the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
February 29, 2024
Issuing agencies
Health and Human Services DepartmentCenters for Disease Control and Prevention
Abstract
In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC) and the Health Resources and Services Administration (HRSA) announce the following meeting of the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment (CHAC). This meeting is open to the public, limited only by the number of audio and web conference lines (1,000 lines are available). Time will be available for public comment (registration is required to provide oral comment).
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 41 (Thursday, February 29, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 41 (Thursday, February 29, 2024)]
[Notices]
[Pages 14844-14845]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-04197]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Meeting of the CDC/HRSA Advisory Committee on HIV, Viral
Hepatitis and STD Prevention and Treatment
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the
Centers for Disease Control and Prevention (CDC) and the Health
Resources and Services Administration (HRSA) announce the following
meeting of the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and
STD Prevention and Treatment (CHAC). This meeting is open to the
public, limited only by the number of audio and web conference lines
(1,000 lines are available). Time will be available for public comment
(registration is required to provide oral comment).
DATES: The meeting will be held on April 9 and 10, 2024, from 9 a.m. to
4:30 p.m., EDT.
Written comments must be submitted by April 19, 2024. Registration
to make oral comments must be submitted by March 26, 2024.
ADDRESSES: The telephone access number is 1-669-254-5252, Webinar ID:
160 972 1316, and the Passcode is 08044152. The web conference access
is <a href="https://cdc.zoomgov.com/j/1609721316?pwd=cUVqdUp5dlBNaDhhWERrcWdXUk9yUT09">https://cdc.zoomgov.com/j/1609721316?pwd=cUVqdUp5dlBNaDhhWERrcWdXUk9yUT09</a>, and the Passcode is
dx%cJGp3. The number of available audio and web conference lines is
1,000.
FOR FURTHER INFORMATION CONTACT: Marah Condit, M.S., Committee
Management Lead, Office of Policy, Planning, and Partnerships, National
Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for
Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US8-6,
Atlanta, Georgia 30329-4027. Telephone: (404) 639-3423; Email:
<a href="/cdn-cgi/l/email-protection#056b666d6d767175756a696c667c456661662b626a73"><span class="__cf_email__" data-cfemail="4f212c27273c3b3f3f2023262c360f2c2b2c61282039">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
Purpose: The CDC/HRSA Advisory Committee on HIV, Viral Hepatitis
and STD Prevention and Treatment (CHAC) is charged with advising the
Secretary of Health and Human Services; the Director, Centers for
Disease Control and Prevention (CDC); and the Administrator, Health
Resources and Services Administration (HRSA), regarding objectives,
strategies, policies, and priorities for HIV, viral hepatitis, and STD
prevention and treatment efforts including (1) surveillance; (2)
epidemiologic, behavioral, health services, and laboratory research;
(3) identification of policy issues and opportunities related to
prevention and treatment including but not limited to professional
education, healthcare delivery, social determinants of health,
research, and prevention and treatment services; (4) strategic issues
influencing the ability of CDC and HRSA to fulfill their missions; (5)
development and implementation of federal programs focused on
prevention and treatment; and (6) provide support to the agencies in
their response to emerging health needs.
Matters to be Considered: The agenda will include discussions on
(1) syndemic approach to testing, (2) using prescription data to
support the HIV care continuum, (3) HIV and aging, (4) an update on
DoxyPEP, (5) advancing diagnosis of hepatitis C virus infection, (6) an
update from the Long-Acting Injectable Workgroup, (7) an update from
the Community Partnerships Workgroup, (8) an update from the
[[Page 14845]]
Workforce Workgroup, and (9) an update from the Presidential Advisory
Council on HIV/AIDS. Agenda items are subject to change as priorities
dictate.
Public Participation
Written Public Comment: Members of the public are welcome to submit
written comments in advance of the meeting. Written comments must be
submitted by emailing <a href="/cdn-cgi/l/email-protection#5d333e35352e292d2d3231343e241d3e393e733a322b"><span class="__cf_email__" data-cfemail="e08e838888939490908f8c898399a0838483ce878f96">[email protected]</span></a> with subject line ``Spring
CHAC Public Comment Registration'' by April 19, 2024.
Oral Public Comment: Individuals who would like to make an oral
comment during the public comment period must register by emailing
<a href="/cdn-cgi/l/email-protection#ec828f84849f989c9c8380858f95ac8f888fc28b839a"><span class="__cf_email__" data-cfemail="5638353e3e25222626393a3f352f1635323578313920">[email protected]</span></a> with subject line ``Spring CHAC Public Comment
Registration'' by March 26, 2024. The public comment period is on April
9, 2024, at 3:45 p.m., EDT.
The Director, Office of Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-04197 Filed 2-28-24; 8:45 am]
BILLING CODE 4163-18-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on February 29, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.